3 ms·
So, I don't know much about pharma or the US drug development/purchase systems. And I don't know if this drug is under or over priced. But before we just look
by LatteLazy 7y ago
So, I don't know much about pharma or the US drug development/purchase systems. And I don't know if this drug is under or over priced. But before we just look at single numbers and declare them insane, we should really think quite carefully...
The generic alternative costs about $9000 a year, so it's clearly a difficult drug to manufacture and supply. And 100k a year makes a great headline, but what does the average consumer actually pay? 100k a year is the starting point for negotiations for insurance companies not the price they pay. Wikipedia says the NHS (UK) is getting it for about 30k USD and the average in the US was 85k USD
https://en.wikipedia.org/wiki/Imatinib https://en.wikipedia.org/wiki/Imatinib
Plus, Companies profit or die based on revenue and costs, not prices alone. Since only about 6000 people a year get the main form of Leukemia this drug was developed to treat, it's pretty niche. Assuming all 6000 people are diagnosed in time and all are treated with this drug and all pay the 85k (or their insurer does), that gets you $510m a year.
But wait! We already said it costs about 10k for the generic. So when you take that off, the gross profit is $450m (per year for the US market).
Multiply that up by the 10 year average use span and you get 4.5bn a year and a 10 year patent gives you 45bn. Very juicy!
Except that developing a new drug costs 5-10bn USD
https://en.wikipedia.org/wiki/Cost_of_drug_development https://en.wikipedia.org/wiki/Cost_of_drug_development
And the success rate is something like 38% from Academia to Approval. So if you spend 7bn each on three drugs, it's cost you 21bn to develop the one that gets approved.
So about half of that juicy 45bn is gone just on development costs. Plus you're investing in development for a product that won't sell for maybe a decade and you need to factor in the risks (that none of your drugs work, that someone else beats you to market, that a better drug comes along, that some other treatment cures the disease you're targeting, that your drug works but turns out to be toxic in some other way and you have a huge lawsuit to settle).
Suddenly, if I were an investor, that 85k average price suddenly looks ok but not amazing. And remember, the price hasn't been 85k the whole time, it was 24k (or rather it was whatever insurers negotiated below 24k) in year one.
- endothrowho333 7y agoThis math rests on two constants being true: 1. The generic for Gleevec (imatinib mesylate) costing $9k 2. Gleevec costing $100k retail Neither of which have been true since Gleevec went generic (sensationalist reporting). Brandname imatinib mesylate costs $9-12k depending on insurance. You can get a rebate card that lowers that to around $200. Generic it's around $100-150 for a month's supply. I really dislike pharmaceutical practices, but there are systems already in place that will allow actual "consumers" (patients, not hospitals and other orgs) to pay a reasonable price for the medication they need. This really is no different than the Shkreli debacle.
- LatteLazy 7y agoReally, the maths only relies on the cost of new drug development and the number of (potential) users per year. Everything else is minor. For instance, if the cost of producing and supplying the drug were different, that would add only 10 percent to the final profit, that is easily offset by factoring in inflation. And that's the point here: developing drugs is expensive and risky. So you need a big potential profit to do it. That means big revenue. Big revenue and small numbers of users means high prices.